Concepts (95)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Scedosporium | 1 | 2021 | 10 | 0.800 |
Why?
|
| Gallbladder Neoplasms | 1 | 2021 | 190 | 0.650 |
Why?
|
| Skin Neoplasms | 7 | 2024 | 5797 | 0.350 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 2018 | 301 | 0.280 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 11141 | 0.260 |
Why?
|
| Collagen Diseases | 1 | 2024 | 39 | 0.240 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2024 | 114 | 0.210 |
Why?
|
| Hepatitis B | 2 | 2018 | 701 | 0.200 |
Why?
|
| Hyphae | 1 | 2021 | 52 | 0.200 |
Why?
|
| Chickenpox | 1 | 2022 | 98 | 0.190 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2018 | 2127 | 0.190 |
Why?
|
| Pancytopenia | 1 | 2022 | 101 | 0.190 |
Why?
|
| Pruritus | 1 | 2024 | 377 | 0.190 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2023 | 237 | 0.190 |
Why?
|
| Post-Exposure Prophylaxis | 2 | 2018 | 104 | 0.180 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2018 | 1349 | 0.180 |
Why?
|
| Hepatitis B Vaccines | 2 | 2018 | 186 | 0.180 |
Why?
|
| Chile | 1 | 2021 | 254 | 0.170 |
Why?
|
| Melanoma | 3 | 2023 | 5695 | 0.170 |
Why?
|
| Herpes Zoster | 1 | 2022 | 251 | 0.170 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2023 | 321 | 0.170 |
Why?
|
| Republic of Korea | 1 | 2021 | 567 | 0.160 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2024 | 1115 | 0.150 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2024 | 4024 | 0.150 |
Why?
|
| Antifungal Agents | 1 | 2021 | 746 | 0.140 |
Why?
|
| Precancerous Conditions | 1 | 2023 | 978 | 0.130 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 857 | 0.130 |
Why?
|
| Renal Dialysis | 1 | 2024 | 1802 | 0.120 |
Why?
|
| Observer Variation | 1 | 2021 | 2596 | 0.120 |
Why?
|
| Syphilis | 1 | 2017 | 240 | 0.120 |
Why?
|
| Guam | 3 | 2018 | 30 | 0.120 |
Why?
|
| Prenatal Care | 2 | 2018 | 1128 | 0.110 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 2368 | 0.110 |
Why?
|
| Neoadjuvant Therapy | 1 | 2024 | 2811 | 0.110 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2017 | 628 | 0.100 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 3826 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2024 | 11064 | 0.090 |
Why?
|
| Cause of Death | 1 | 2021 | 3723 | 0.090 |
Why?
|
| Prenatal Diagnosis | 1 | 2017 | 1262 | 0.090 |
Why?
|
| Software | 1 | 2024 | 4420 | 0.090 |
Why?
|
| Health Status Disparities | 1 | 2021 | 1819 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 3381 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 15273 | 0.060 |
Why?
|
| Skin Diseases, Genetic | 1 | 2024 | 49 | 0.060 |
Why?
|
| Retrospective Studies | 5 | 2024 | 80301 | 0.060 |
Why?
|
| Humans | 17 | 2024 | 760261 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 20048 | 0.050 |
Why?
|
| Mass Screening | 1 | 2017 | 5422 | 0.050 |
Why?
|
| Herpesvirus 3, Human | 1 | 2022 | 159 | 0.050 |
Why?
|
| Middle Aged | 7 | 2024 | 220175 | 0.040 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2022 | 259 | 0.040 |
Why?
|
| Exanthema | 1 | 2024 | 504 | 0.040 |
Why?
|
| Immunoglobulin A | 1 | 2023 | 978 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2021 | 24086 | 0.040 |
Why?
|
| Necrosis | 1 | 2023 | 1612 | 0.040 |
Why?
|
| Time Factors | 1 | 2021 | 40133 | 0.040 |
Why?
|
| Female | 9 | 2024 | 391011 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2023 | 1529 | 0.040 |
Why?
|
| Endemic Diseases | 1 | 2018 | 191 | 0.040 |
Why?
|
| Immunization Schedule | 1 | 2017 | 225 | 0.030 |
Why?
|
| Aged | 3 | 2024 | 168995 | 0.030 |
Why?
|
| Male | 5 | 2024 | 359413 | 0.030 |
Why?
|
| Neonatal Screening | 1 | 2018 | 595 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2021 | 64947 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2017 | 863 | 0.030 |
Why?
|
| Chlamydia Infections | 1 | 2017 | 362 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2022 | 1843 | 0.030 |
Why?
|
| Risk Factors | 1 | 2021 | 74269 | 0.030 |
Why?
|
| Gonorrhea | 1 | 2017 | 342 | 0.030 |
Why?
|
| United States | 1 | 2021 | 72363 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2023 | 3491 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2024 | 2469 | 0.020 |
Why?
|
| Computational Biology | 1 | 2024 | 3504 | 0.020 |
Why?
|
| Pregnancy | 3 | 2018 | 29725 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2023 | 3145 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 4546 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2024 | 41317 | 0.020 |
Why?
|
| Thyroid Neoplasms | 1 | 2024 | 2332 | 0.020 |
Why?
|
| Skin | 1 | 2023 | 4468 | 0.020 |
Why?
|
| Adult | 5 | 2024 | 219847 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2024 | 4637 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2023 | 14656 | 0.020 |
Why?
|
| Young Adult | 3 | 2018 | 58673 | 0.020 |
Why?
|
| Adolescent | 3 | 2018 | 87747 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 9274 | 0.020 |
Why?
|
| Incidence | 1 | 2023 | 21378 | 0.010 |
Why?
|
| Prevalence | 1 | 2018 | 15687 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2022 | 17766 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 58947 | 0.010 |
Why?
|
| Mutation | 1 | 2023 | 29950 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2018 | 26168 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 21065 | 0.010 |
Why?
|
| Infant | 1 | 2017 | 36030 | 0.010 |
Why?
|
| Neoplasms | 1 | 2024 | 22066 | 0.010 |
Why?
|
| HIV Infections | 1 | 2017 | 17159 | 0.010 |
Why?
|
Concepts
(95)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(60)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_